PT1849470T - Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase - Google Patents
Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilaseInfo
- Publication number
- PT1849470T PT1849470T PT67122929T PT06712292T PT1849470T PT 1849470 T PT1849470 T PT 1849470T PT 67122929 T PT67122929 T PT 67122929T PT 06712292 T PT06712292 T PT 06712292T PT 1849470 T PT1849470 T PT 1849470T
- Authority
- PT
- Portugal
- Prior art keywords
- alpha
- trifluorotimidin
- timidine
- anticancer drug
- drug containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/042,059 US7799783B2 (en) | 2005-01-26 | 2005-01-26 | Method of administrating an anticancer drug containing α, α, α-trifluorothymidine and thymidine phosphorylase inhibitor |
| JP2005165156 | 2005-06-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1849470T true PT1849470T (pt) | 2017-09-22 |
Family
ID=36740357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT67122929T PT1849470T (pt) | 2005-01-26 | 2006-01-25 | Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase |
Country Status (21)
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
| US20070048228A1 (en) | 2003-08-06 | 2007-03-01 | Elisabeth Arkenau-Maric | Abuse-proofed dosage form |
| DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE10336400A1 (de) | 2003-08-06 | 2005-03-24 | Grünenthal GmbH | Gegen Missbrauch gesicherte Darreichungsform |
| DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
| DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
| DK1849470T4 (en) | 2005-01-26 | 2024-04-02 | Taiho Pharmaceutical Co Ltd | Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor |
| DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
| DE102007011485A1 (de) | 2007-03-07 | 2008-09-11 | Grünenthal GmbH | Darreichungsform mit erschwertem Missbrauch |
| PL2148676T3 (pl) | 2007-04-25 | 2016-12-30 | Stosowanie sapacytabiny do leczenia choroby proliferacyjnej | |
| MX2010008138A (es) | 2008-01-25 | 2010-08-10 | Gruenenthal Gmbh | Forma de dosis farmaceutica. |
| TWI524904B (zh) | 2008-05-09 | 2016-03-11 | 歌林達股份有限公司 | 製備醫藥用固體劑型，尤指錠劑之方法，及製備固體劑型，尤指錠劑之前驅物之方法 |
| US20110065663A1 (en) * | 2008-05-15 | 2011-03-17 | Katholieke Universiteit Leuven, K.U. Leuven R&D | Anti-cancer combination therapy |
| CA2765971C (en) | 2009-07-22 | 2017-08-22 | Gruenenthal Gmbh | Hot-melt extruded controlled release dosage form |
| EP2456425B1 (en) | 2009-07-22 | 2015-10-21 | Grünenthal GmbH | Tamper-resistant dosage form for oxidation-sensitive opioids |
| EP2611426B1 (en) | 2010-09-02 | 2014-06-25 | Grünenthal GmbH | Tamper resistant dosage form comprising inorganic salt |
| KR20130137627A (ko) | 2010-09-02 | 2013-12-17 | 그뤼넨탈 게엠베하 | 음이온성 중합체를 포함하는 내변조성 투여형 |
| KR20140053159A (ko) | 2011-07-29 | 2014-05-07 | 그뤼넨탈 게엠베하 | 즉시 약물 방출을 제공하는 탬퍼-저항성 정제 |
| CN103857386A (zh) | 2011-07-29 | 2014-06-11 | 格吕伦塔尔有限公司 | 提供药物立即释放的抗破碎片剂 |
| KR101693090B1 (ko) * | 2011-08-16 | 2017-01-04 | 다이호야쿠힌고교 가부시키가이샤 | Kras 유전자 변이형의 결장 직장암 환자에 대한 항종양제 및 치료 효과 예측 방법 |
| TWI526210B (zh) | 2012-02-15 | 2016-03-21 | Taiho Pharmaceutical Co Ltd | Oral pharmaceutical composition |
| TWI503122B (zh) | 2012-02-15 | 2015-10-11 | Taiho Pharmaceutical Co Ltd | Oral administration of pharmaceutical compositions |
| EP2819656A1 (en) | 2012-02-28 | 2015-01-07 | Grünenthal GmbH | Tamper-resistant dosage form comprising pharmacologically active compound and anionic polymer |
| US9340808B2 (en) | 2012-03-14 | 2016-05-17 | Nisshin Pharma Inc. | Sulfur amino acid-containing composition |
| PT2838512T (pt) | 2012-04-18 | 2018-11-09 | Gruenenthal Gmbh | Forma farmacêutica resistente à adulteração e resistente à libertação inesperada de alta quantidade (dose-dumping) |
| US10064945B2 (en) | 2012-05-11 | 2018-09-04 | Gruenenthal Gmbh | Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc |
| US10213432B2 (en) | 2012-05-16 | 2019-02-26 | Novartis Ag | Dosage regimen for a PI-3 kinase inhibitor |
| KR101847252B1 (ko) | 2013-03-27 | 2018-04-09 | 다이호야쿠힌고교 가부시키가이샤 | 이리노테칸염산염 수화물을 함유하는 항종양제 |
| AU2014245147B2 (en) * | 2013-03-27 | 2017-08-31 | Les Laboratoires Servier | Antitumor agent including low-dose irinotecan hydrochloride hydrate |
| KR101928618B1 (ko) | 2013-05-17 | 2018-12-12 | 다이호야쿠힌고교 가부시키가이샤 | Tk1 단백질의 발현이 항진된 결장직장암 환자에 대한 치료효과 예측 방법 |
| AU2014273227B2 (en) | 2013-05-29 | 2019-08-15 | Grunenthal Gmbh | Tamper-resistant dosage form containing one or more particles |
| AU2014273226B2 (en) | 2013-05-29 | 2019-06-27 | Grunenthal Gmbh | Tamper resistant dosage form with bimodal release profile |
| EP3019157A1 (en) | 2013-07-12 | 2016-05-18 | Grünenthal GmbH | Tamper-resistant dosage form containing ethylene-vinyl acetate polymer |
| EP4201424A1 (en) | 2013-09-06 | 2023-06-28 | Taiho Pharmaceutical Co., Ltd. | Antitumor agent and antitumor effect enhancer |
| CN105934241B (zh) | 2013-11-26 | 2020-06-05 | 格吕伦塔尔有限公司 | 通过低温研磨制备粉末状药物组合物 |
| CN106572980A (zh) | 2014-05-12 | 2017-04-19 | 格吕伦塔尔有限公司 | 包含他喷他多的防篡改即释胶囊制剂 |
| MX2016015417A (es) | 2014-05-26 | 2017-02-22 | Gruenenthal Gmbh | Multiparticulas protegidas contra vertido de dosis etanolico. |
| US20160310429A1 (en) | 2015-04-24 | 2016-10-27 | Grünenthal GmbH | Tamper-resistant dosage form with immediate release and resistance against solvent extraction |
| AU2016319203A1 (en) | 2015-09-10 | 2018-02-22 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
| JP6871868B2 (ja) * | 2016-01-08 | 2021-05-19 | 大鵬薬品工業株式会社 | 免疫調節剤を含有する抗腫瘍剤及び抗腫瘍効果増強剤 |
| RU2727598C2 (ru) | 2016-02-05 | 2020-07-22 | Тайхо Фармасьютикал Ко., Лтд. | Способ лечения больных раком с тяжелой почечной недостаточностью |
| EP3730935A4 (en) | 2017-12-22 | 2022-02-23 | Taiho Pharmaceutical Co., Ltd. | METHOD OF DETECTING ANALOGUES OF TRIFLURIDIN AND/OR TIPIRACIL |
| US10866219B2 (en) | 2017-12-22 | 2020-12-15 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine- and/or tipiracil-related substance |
| US10816517B2 (en) | 2018-01-05 | 2020-10-27 | Taiho Pharmaceutical Co., Ltd. | Method for detecting trifluridine-related substance by high-performance liquid chromatography |
| WO2019135405A1 (ja) | 2018-01-05 | 2019-07-11 | 大鵬薬品工業株式会社 | トリフルリジン由来の類縁物質の検出方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3088757B2 (ja) * | 1995-03-29 | 2000-09-18 | 大鵬薬品工業株式会社 | ウラシル誘導体並びにそれを含有する抗腫瘍効果増強剤及び抗腫瘍剤 |
| KR100284413B1 (ko) * | 1996-09-24 | 2001-03-02 | 고바야시 유키오 | 우라실 유도체를 함유하는 암전이 억제제유도체 |
| DK1849470T4 (en) | 2005-01-26 | 2024-04-02 | Taiho Pharmaceutical Co Ltd | Cancerlægemiddel, som indeholder alpha, alpha, alpha-trifluorthymidin og thymidin-phosphorylase-inhibitor |
-
2006
- 2006-01-25 DK DK06712292.9T patent/DK1849470T4/da active
- 2006-01-25 SI SI200632192T patent/SI1849470T2/sl unknown
- 2006-01-25 ES ES06712292T patent/ES2630002T5/es not_active Expired - Lifetime
- 2006-01-25 JP JP2007500529A patent/JP5576591B2/ja not_active Expired - Lifetime
- 2006-01-25 RU RU2007132181/15A patent/RU2394581C2/ru active
- 2006-01-25 PT PT67122929T patent/PT1849470T/pt unknown
- 2006-01-25 EP EP06712292.9A patent/EP1849470B2/en not_active Expired - Lifetime
- 2006-01-25 CA CA002594713A patent/CA2594713A1/en not_active Withdrawn
- 2006-01-25 LT LTEP06712292.9T patent/LT1849470T/lt unknown
- 2006-01-25 AU AU2006209547A patent/AU2006209547C1/en not_active Expired
- 2006-01-25 PL PL06712292.9T patent/PL1849470T5/pl unknown
- 2006-01-25 WO PCT/JP2006/301097 patent/WO2006080327A1/ja not_active Ceased
- 2006-01-25 HU HUE06712292A patent/HUE033306T2/hu unknown
- 2006-01-26 TW TW095103114A patent/TWI362265B/zh active
-
2007
- 2007-07-19 KR KR1020077016492A patent/KR101468216B1/ko not_active Expired - Lifetime
-
2017
- 2017-07-28 LT LTPA2017024 patent/LTC1849470I2/lt unknown
- 2017-08-01 HU HUS1700032C patent/HUS1700032I1/hu unknown
- 2017-08-03 BE BE2017C028C patent/BE2017C028I2/fr unknown
- 2017-08-08 NL NL300889C patent/NL300889I2/nl unknown
- 2017-08-08 FR FR17C1028C patent/FR17C1028I2/fr active Active
- 2017-09-06 FI FIEP06712292.9T patent/FI1849470T4/fi active
- 2017-09-07 CY CY20171100947T patent/CY1119393T1/el unknown
- 2017-09-07 CY CY2017029C patent/CY2017029I1/el unknown
- 2017-09-29 LU LU00036C patent/LUC00036I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1849470T (pt) | Fármaco anticancro contendo alfa, alfa, alfa-trifluorotimidina e inibidor da timidina-fosforilase | |
| DK1907037T3 (da) | Medikamentdispenser. | |
| HUS1400051I1 (hu) | Lurazidont tartalmazó gyógyászati készítmény | |
| BRPI0815773A2 (pt) | composto, e, medicamento. | |
| EP1992348A4 (en) | PHARMACEUTICAL COMBINATION | |
| NL2000480A1 (nl) | Nieuwe farmaceutische middelen. | |
| DE602006004866D1 (de) | Katheter | |
| DK2254873T3 (da) | Benzodiazepinforbindelse og farmaceutisk sammensætning. | |
| DK1957073T3 (da) | Lægemiddel | |
| DE602006020744D1 (de) | Fertigspritze | |
| DK2029561T3 (da) | Tricyclisk forbindelse og farmaceutisk anvendelse deraf | |
| DK1757293T3 (da) | Bh4-responsiv hyperphenylalaninæmi-medikamenter | |
| NL1032915A1 (nl) | Katheterpunt. | |
| EP1937255A4 (en) | PHARMACEUTICAL COMPOSITION | |
| EP1862184A4 (en) | PHARMACEUTICAL COMPOSITION | |
| BRPI0614413A2 (pt) | composto, e, composição farmacêutica | |
| EP1941909A4 (en) | PREVENTIVE MEASURES / REMEDIES FOR CANCER | |
| BRPI0614412A2 (pt) | composto, e, composição farmacêutica | |
| ITMI20040943A1 (it) | Composizione farmaceutica cicatrizzante | |
| DE112006001760A5 (de) | Katheter | |
| DK1720557T3 (da) | Hurtig-opløselig, smagsmaskeret tablet | |
| UA11573S (uk) | Етикетка лікарського засобу | |
| BRPI0719398A2 (pt) | Composição farmacêutica. | |
| EP1889632A4 (en) | MEANS FOR THE TREATMENT OF XANTHOM | |
| UA10369S (uk) | Таблетка фармацевтична |